EQT to acquire Adalvo, a leading B2B dossier developer

EQT Sweden

EQT X to acquire Adalvo, a rapidly growing, asset-light B2B dossier developer providing market-approval-ready generic drug dossiers to pharmaceutical companies           EQT will support Adalvo's next phase of growth, further investing in R&D and innovation, and advancing the operational scale-up of the business            Adalvo is uniquely positioned as a one-stop partner, combining strong business development capabilities with a flexible, customer-centric model to meet the bespoke needs of pharmaceutical companies worldwide           Adalvo plays an important role in increasing access to affordable healthcare by developing and distributing generic drugs at affordable prices across a wide range of markets. The transaction highlights EQT's commitment to partnering with companies that deliver critical services to societyView original content:https://www.prnewswire.co.uk/news-releases/eqt-to-acquire-adalvo-a-leading-b2b-dossier-developer-302508580.html